A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma

Summary Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to...

Full description

Saved in:
Bibliographic Details
Published inInvestigational new drugs Vol. 38; no. 2; pp. 264 - 273
Main Authors Hsu, Yen-Bin, Lan, Ming-Chin, Kuo, Yu-Lun, Huang, Chi-Ying F., Lan, Ming-Ying
Format Journal Article
LanguageEnglish
Published New York Springer US 01.04.2020
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0167-6997
1573-0646
1573-0646
DOI10.1007/s10637-019-00779-3

Cover

Loading…
Abstract Summary Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.
AbstractList Summary Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.
Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.
Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.
SummaryBackground Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.
Author Kuo, Yu-Lun
Lan, Ming-Ying
Hsu, Yen-Bin
Huang, Chi-Ying F.
Lan, Ming-Chin
Author_xml – sequence: 1
  givenname: Yen-Bin
  surname: Hsu
  fullname: Hsu, Yen-Bin
  organization: Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University
– sequence: 2
  givenname: Ming-Chin
  surname: Lan
  fullname: Lan, Ming-Chin
  organization: Department of Otolaryngology-Head and Neck Surgery, Buddhist Tzu Chi Medical Foundation, Taipei Tzu Chi Hospital, School of Medicine, Tzu Chi University
– sequence: 3
  givenname: Yu-Lun
  surname: Kuo
  fullname: Kuo, Yu-Lun
  organization: Biotools, Co., Ltd
– sequence: 4
  givenname: Chi-Ying F.
  surname: Huang
  fullname: Huang, Chi-Ying F.
  email: cyhuang5@ym.edu.tw
  organization: Institute of Clinical Medicine, National Yang-Ming University, Institute of Biopharmaceutical Sciences, National Yang-Ming University
– sequence: 5
  givenname: Ming-Ying
  orcidid: 0000-0001-5565-9580
  surname: Lan
  fullname: Lan, Ming-Ying
  email: mingyinglan@gmail.com
  organization: Department of Otolaryngology-Head and Neck Surgery, Taipei Veterans General Hospital, School of Medicine, National Yang-Ming University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30993588$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9r3DAQxUVJaTZ_vkAPxdBLDnE7I8mWdQwhaQuBXtpTD0LWzjYKXsmV5EK_fbS7CYUcchIa_d7w9N4JOwoxEGPvET4hgPqcEXqhWkDd1qvSrXjDVtgp0UIv-yO2AuxV22utjtlJzg8AILSS79ixAK1FNwwr9uuqmRO5yQfv7NTQXzsttvgYmrhpyr2PuSSaSwyXjW2CLUuqlA3Fjz4W7y4bH-o4x_nepn_hN9VXZ5PzIW7tGXu7sVOm86fzlP28vflx_bW9-_7l2_XVXeukxNIOmwGkIyA7unXfIXSWd2rkFiTwAXeukUa-pt2cD71zclQ4kCbLgRSKU3Zx2Dun-GehXMzWZ0fTZAPFJRvOEXSHspMV_fgCfYhLCtXdnuKIPfBKfXiilnFLazMnv63fM8-xVWA4AC7FnBNtjPNlH1tJ1k8GwewaMoeGTG3I7Bsyokr5C-nz9ldF4iDKFa4pp_-2X1E9As2Zoic
CitedBy_id crossref_primary_10_1016_j_ejphar_2021_174661
crossref_primary_10_1002_cjoc_202100496
crossref_primary_10_1002_hed_27238
crossref_primary_10_1007_s10787_024_01587_9
crossref_primary_10_1039_D4RA01496K
crossref_primary_10_1016_j_chembiol_2020_07_003
crossref_primary_10_69601_meandrosmdj_1540223
crossref_primary_10_1155_2019_7457013
Cites_doi 10.4161/cc.8.12.8708
10.1371/journal.pone.0132839
10.1016/j.ajpath.2010.11.010
10.1158/1535-7163.MCT-08-0188
10.1002/path.2355
10.1002/ijc.28839
10.1007/s00432-014-1872-3
10.3892/or.2017.5480
10.1002/mc.22622
10.3892/mmr.2015.3469
10.1155/2010/930509
10.1158/1535-7163.MCT-09-0966
10.1007/s00066-015-0840-4
10.4161/cbt.11.1.13854
10.1158/0008-5472.CAN-05-3138
10.1186/s12944-018-0697-5
10.3892/or.2015.3834
10.1016/j.canlet.2016.01.040
10.1002/jgm.2614
10.1016/j.surg.2005.10.012
10.1158/1535-7163.MCT-11-0536
10.4161/cc.9.6.10955
10.1111/jcmm.12602
10.1038/emboj.2009.239
10.1101/gad.1200704
10.1016/j.ejphar.2016.06.052
10.1097/IGC.0000000000000969
10.1371/journal.pone.0005592
10.1039/C4QO00288A
10.1371/journal.pone.0006593
10.4161/cbt.13.3.18875
10.3892/or.2014.3357
10.1016/j.bcp.2012.01.027
10.1186/1476-4598-8-37
10.4161/cc.8.17.9414
10.1016/j.bbcan.2016.12.002
10.1007/978-3-540-92810-2
10.1002/hed.20833
10.1038/cddis.2015.155
10.1038/onc.2016.495
10.1158/0008-5472.CAN-05-3003
10.1158/0008-5472.CAN-05-2912
10.1093/nar/22.3.357
10.1038/nrc2223
10.1371/journal.pone.0004849
10.1158/0008-5472.CAN-04-4059
10.3109/03009734.2014.960053
10.1158/1541-7786.MCR-13-0008
10.18632/oncotarget.16147
10.18632/oncotarget.10078
10.18632/oncotarget.2957
10.1002/hed.23464
ContentType Journal Article
Copyright Springer Science+Business Media, LLC, part of Springer Nature 2019
Investigational New Drugs is a copyright of Springer, (2019). All Rights Reserved.
Copyright_xml – notice: Springer Science+Business Media, LLC, part of Springer Nature 2019
– notice: Investigational New Drugs is a copyright of Springer, (2019). All Rights Reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QO
7RV
7WY
7WZ
7X7
7XB
87Z
88E
8AO
8FD
8FI
8FJ
8FK
8FL
ABUWG
AFKRA
AZQEC
BENPR
BEZIV
CCPQU
DWQXO
FR3
FRNLG
FYUFA
F~G
GHDGH
K60
K6~
K9-
K9.
KB0
L.-
M0C
M0R
M0S
M1P
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQBIZ
PQBZA
PQEST
PQQKQ
PQUKI
Q9U
7X8
DOI 10.1007/s10637-019-00779-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Nursing & Allied Health Database
ABI/INFORM Collection
ABI/INFORM Global (PDF only)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ABI/INFORM Global (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ABI/INFORM Collection (Alumni Edition)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Business Premium Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Business Premium Collection (Alumni)
Health Research Premium Collection
ABI/INFORM Global (Corporate)
Health Research Premium Collection (Alumni)
ProQuest Business Collection (Alumni Edition)
ProQuest Business Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ABI/INFORM Professional Advanced
ABI/INFORM Global
Consumer Health Database
Health & Medical Collection (Alumni)
Medical Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Business
ProQuest One Business (Alumni)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ABI/INFORM Global (Corporate)
ProQuest Business Collection (Alumni Edition)
ProQuest One Business
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ABI/INFORM Complete
ProQuest Central
ABI/INFORM Professional Advanced
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ABI/INFORM Complete (Alumni Edition)
Business Premium Collection
ABI/INFORM Global
ABI/INFORM Global (Alumni Edition)
ProQuest Central Basic
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Business Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Business (Alumni)
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
Business Premium Collection (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
ABI/INFORM Global (Corporate)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-0646
EndPage 273
ExternalDocumentID 30993588
10_1007_s10637_019_00779_3
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Taipei Veterans General Hospital
  grantid: V105-B–022 and V108C-088
  funderid: http://dx.doi.org/10.13039/501100011912
– fundername: Ministry of Science and Technology, Taiwan
  grantid: MOST 106-2314-B-075 -035 -MY3; MOST 107-2320-B-010-040-MY3
  funderid: http://dx.doi.org/10.13039/501100004663
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
1SB
203
28-
29J
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7RV
7WY
7X7
88E
8AO
8FI
8FJ
8FL
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BEZIV
BGNMA
BKEYQ
BKNYI
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
EPAXT
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRNLG
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GROUPED_ABI_INFORM_COMPLETE
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K60
K6~
K9-
KDC
KOV
KOW
KPH
LAK
LLZTM
M0C
M0R
M1P
M4Y
MA-
MK0
N2Q
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQBIZ
PQBZA
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK6
WK8
WOW
YLTOR
Z45
Z7U
Z81
Z82
Z87
Z8O
Z8U
Z8V
Z91
ZGI
ZMTXR
ZOVNA
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7XB
8FD
8FK
ABRTQ
FR3
K9.
L.-
P64
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c441t-8f804ce0eabcd65105a257b2a04028100031eb2de5a25286cc4b718e9ea20e713
IEDL.DBID 7X7
ISSN 0167-6997
1573-0646
IngestDate Tue Aug 05 10:18:44 EDT 2025
Sat Aug 23 12:42:40 EDT 2025
Thu Apr 03 06:55:27 EDT 2025
Tue Jul 01 03:15:30 EDT 2025
Thu Apr 24 23:07:30 EDT 2025
Fri Feb 21 02:33:57 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Nasopharyngeal carcinoma
Anticancer drug
Microarray
Thiostrepton
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c441t-8f804ce0eabcd65105a257b2a04028100031eb2de5a25286cc4b718e9ea20e713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5565-9580
PMID 30993588
PQID 2210211602
PQPubID 37283
PageCount 10
ParticipantIDs proquest_miscellaneous_2210951454
proquest_journals_2210211602
pubmed_primary_30993588
crossref_citationtrail_10_1007_s10637_019_00779_3
crossref_primary_10_1007_s10637_019_00779_3
springer_journals_10_1007_s10637_019_00779_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-04-01
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-04-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationSubtitle Novel Anti-Cancer Therapeutics and Therapies
PublicationTitle Investigational new drugs
PublicationTitleAbbrev Invest New Drugs
PublicationTitleAlternate Invest New Drugs
PublicationYear 2020
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Lu, Cooper, Lee (CR2) 2010
Lin, Wong, Chan, Tzung, Ho, Hsu, Chuang (CR22) 1990; 62
Kalin, Wang, Ackerson, Major, Detrisac, Kalinichenko, Lyubimov, Costa (CR31) 2006; 66
Westhoff, Chen, Teng (CR33) 2017; 27
Yin, Liu, Liu, Owzar, Han, Su, Wei, Hung, Brhane, McLaughlin, Brennan, Bickeboeller, Rosenberger, Houlston, Caporaso, Landi, Heinrich, Risch, Christiani, Amos, Wei (CR50) 2017; 56
Kim, Ackerson, Ramakrishna, Tretiakova, Wang, Kalin, Major, Gusarova, Yoder, Costa, Kalinichenko (CR30) 2006; 66
Chan, Yu, Chiu, Yao, Liu, Cheung, Ngan (CR32) 2008; 215
Lan, Chen, Lin, Lee, Yang (CR4) 2010; 9
Wonsey, Follettie (CR29) 2005; 65
Liu, Dai, Kang, Ban, Huang, Lang, Aldape, Xie, Pelloski, Xie, Sawaya, Huang (CR35) 2006; 66
Tang, Chen, Xue, He, Zheng, Zeng, Jia (CR1) 2016; 374
Qiao, Lamore, Cabello, Lesson, Muñoz-Rodriguez, Wondrak (CR40) 2012; 83
Lan, Yang, Lin, Lin, Shann, Ho, Huang (CR5) 2014; 36
Bhat, Halasi, Gartel (CR11) 2009; 4
Han, Jiang, Ma, Wu, Wang (CR48) 2018; 52
Wang, Jia, Xing, Li, Fan (CR37) 2015; 12
Loftus, Dhruv, Tuncali, Kloss, Yang, Schumacher, Cao, Williams, Eschbacher, Ross, Tran (CR54) 2013; 11
Zhou, Shen, Zheng, Wang, Che, Hu, Li (CR52) 2017; 8
Halasi, Zhao, Dahari, Bhat, Gonzalez, Lyubimo, Tonetti, Gartel (CR58) 2010; 9
Kalinichenko, Major, Wang, Petrovic, Kuechle, Yoder, Dennewitz, Shin, Datta, Raychaudhuri, Costa (CR28) 2004; 18
Chou, Lin, Kim, You, Xu, He, Jablons (CR3) 2008; 30
CR8
Verfaillie, Salazar, Velasco, Agostinis (CR43) 2010; 2010
Pandit, Bhat, Gartel (CR12) 2011; 11
Pandit, Gartel (CR13) 2011; 178
Park, Carr, Wang, Nogueira, Hay, Tyner, Lau, Costa, Raychaudhuri (CR25) 2009; 28
Sandu, Chandramouli, Glickman, Molina, Kuo, Kukushkin, Goldberg, Steller (CR41) 2015; 19
Wang, Gartel (CR55) 2011; 10
Hasanov, Chen, Chowdhury, Weldon, Ding, Jonasch, Sen, Walker, Dere (CR15) 2017; 36
Jiang, Wang, Chen (CR18) 2014; 119
Nuhn, Künzli, Hennig, Mitkus, Ramanauskas (CR45) 2009; 8
Yu, Chen, Yie, Wei, Wen (CR19) 2015; 33
Halasi, Schraufnagel, Gartel (CR56) 2009; 8
Douard, Moutereau, Pernet, Chimingqi, Allory, Manivet, Conti, Vaubourdolle, Cugnenc, Loric (CR34) 2006; 139
Halasi, Gartel (CR26) 2009; 8
Jo, Park, Kim (CR46) 2016; 788
Wang, Gartel (CR57) 2012; 13
Myatt, Lam (CR27) 2007; 7
Jiang, Wu, Wang, Wen, Yu, Wei, Chen (CR39) 2015; 141
Bhat, Halasi, Gartel (CR10) 2009; 4
Wang, Zheng, Wang, Zhao, Li, Yu, Wang, Liu (CR6) 2015; 2
Park, Lim, Ahn, Hwang (CR51) 2015; 10
Bhat, Chaudhary, Kumar, O'Malley, Inigo (CR44) 2017; 1867
Chiu, Huang, Tsai, Chen, Chang, Huang, Hsu, Chou (CR16) 2015; 6
Katoh, Katoh (CR24) 2004; 25
Jiang, Wang, Chen, Chen (CR17) 2014; 7
Schön, Flierman, Ofner, Stahringer, Holdt, Kolligs, Herbst (CR53) 2014; 135
Chen, Yang, Yu, Xie, Hu, Zeng, Tan (CR20) 2012; 14
Huang, Li, Luo, Hou, Zeng, Li, Mai, Zhang (CR21) 2015; 191
Ju, Huang, Huang, Su (CR14) 2015; 6
Zhu (CR36) 2014; 32
Rosendahl, Douthwaite (CR7) 1994; 22
Lin, Chan, Chen, Huang, Wu, Hsu, Chuang, Wang (CR23) 1993; 68
Gemenetzidis, Bose, Riaz, Chaplin, Young, Ali, Sugden, Thurlow, Cheong, Teo, Wan, Waseem, Parkinson, Fortune, Teh (CR38) 2009; 4
Jang, Hong, Kim, Kim, Jang, Park, Byun, Koh, Choi, Kae, Lee (CR47) 2016; 7
Qureshi, Zuvanich, Khan, Mushtaq, Silswal, Qureshi (CR42) 2018; 17
Kwok, Myatt, Marson, Coombes, Constantinidou, Lam (CR9) 2008; 7
Shiiba, Yamagami, Yamamoto, Minakawa, Okamoto, Kasamatsu, Sakamoto, Uzawa, Takiguchi, Tanzawa (CR49) 2017; 37
JJ Lu (779_CR2) 2010
HJ Park (779_CR25) 2009; 28
E Hasanov (779_CR15) 2017; 36
GL Westhoff (779_CR33) 2017; 27
IM Kim (779_CR30) 2006; 66
L Jiang (779_CR39) 2015; 141
EJ Jo (779_CR46) 2016; 788
R Douard (779_CR34) 2006; 139
SY Ju (779_CR14) 2015; 6
H Zhu (779_CR36) 2014; 32
UG Bhat (779_CR10) 2009; 4
VV Kalinichenko (779_CR28) 2004; 18
C Sandu (779_CR41) 2015; 19
MY Lan (779_CR4) 2010; 9
EM Park (779_CR51) 2015; 10
SF Wang (779_CR6) 2015; 2
L Jiang (779_CR17) 2014; 7
TV Kalin (779_CR31) 2006; 66
M Halasi (779_CR26) 2009; 8
B Pandit (779_CR12) 2011; 11
J Chou (779_CR3) 2008; 30
UG Bhat (779_CR11) 2009; 4
M Wang (779_CR55) 2011; 10
M Halasi (779_CR58) 2010; 9
DW Chan (779_CR32) 2008; 215
L Han (779_CR48) 2018; 52
T Verfaillie (779_CR43) 2010; 2010
M Halasi (779_CR56) 2009; 8
M Wang (779_CR57) 2012; 13
M Liu (779_CR35) 2006; 66
M Shiiba (779_CR49) 2017; 37
E Gemenetzidis (779_CR38) 2009; 4
JC Loftus (779_CR54) 2013; 11
AA Qureshi (779_CR42) 2018; 17
S Schön (779_CR53) 2014; 135
CT Lin (779_CR22) 1990; 62
S Zhou (779_CR52) 2017; 8
LL Tang (779_CR1) 2016; 374
MY Lan (779_CR5) 2014; 36
WT Chiu (779_CR16) 2015; 6
JM Kwok (779_CR9) 2008; 7
HJ Jang (779_CR47) 2016; 7
JY Wang (779_CR37) 2015; 12
779_CR8
TA Bhat (779_CR44) 2017; 1867
P Nuhn (779_CR45) 2009; 8
SS Myatt (779_CR27) 2007; 7
G Rosendahl (779_CR7) 1994; 22
H Chen (779_CR20) 2012; 14
L Jiang (779_CR18) 2014; 119
CT Lin (779_CR23) 1993; 68
J Yin (779_CR50) 2017; 56
S Qiao (779_CR40) 2012; 83
M Katoh (779_CR24) 2004; 25
PY Huang (779_CR21) 2015; 191
DR Wonsey (779_CR29) 2005; 65
B Pandit (779_CR13) 2011; 178
C Yu (779_CR19) 2015; 33
References_xml – volume: 8
  start-page: 1966
  year: 2009
  end-page: 1967
  ident: CR26
  article-title: A novel mode of FoxM1 regulation: positive auto-regulatory loop
  publication-title: Cell Cycle
  doi: 10.4161/cc.8.12.8708
– volume: 10
  start-page: e0132839
  year: 2015
  ident: CR51
  article-title: Interacts with nonstructural 4B and regulates hepatitis C virus propagation
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0132839
– volume: 178
  start-page: 355
  year: 2011
  end-page: 360
  ident: CR13
  article-title: Proteasome inhibitors induce p53-independent apoptosis in human cancer cells
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2010.11.010
– volume: 7
  start-page: 2022
  year: 2008
  end-page: 2032
  ident: CR9
  article-title: Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0188
– volume: 215
  start-page: 245
  year: 2008
  end-page: 252
  ident: CR32
  article-title: Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis
  publication-title: J Pathol
  doi: 10.1002/path.2355
– volume: 135
  start-page: 1800
  year: 2014
  end-page: 1811
  ident: CR53
  article-title: β-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28839
– volume: 52
  start-page: 2101
  year: 2018
  end-page: 2109
  ident: CR48
  article-title: The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway
  publication-title: Int J Oncol
– volume: 141
  start-page: 971
  year: 2015
  end-page: 981
  ident: CR39
  article-title: Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-014-1872-3
– volume: 37
  start-page: 2025
  year: 2017
  end-page: 2032
  ident: CR49
  article-title: Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5480
– volume: 56
  start-page: 1663
  year: 2017
  end-page: 1672
  ident: CR50
  article-title: Pathway-analysis of published genome-wide association studies of lung cancer: a potential role for the CYP4F3 locus
  publication-title: Mol Carcinog
  doi: 10.1002/mc.22622
– volume: 12
  start-page: 1457
  year: 2015
  end-page: 1464
  ident: CR37
  article-title: Inhibition of Forkhead box protein M1 by thiostrepton increases chemosensitivity to doxorubicin in T-cell acute lymphoblastic leukemia
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2015.3469
– volume: 2010
  start-page: 930509
  year: 2010
  ident: CR43
  article-title: Linking ER stress to autophagy: potential implications for Cancer therapy
  publication-title: Int J Cell Biol
  doi: 10.1155/2010/930509
– volume: 9
  start-page: 2511
  year: 2010
  end-page: 2523
  ident: CR4
  article-title: From NPC therapeutic target identification to potential treatment strategy
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0966
– ident: CR8
– volume: 36
  start-page: 1398
  year: 2014
  end-page: 1407
  ident: CR5
  article-title: Using computational strategies to predict potential drugs for nasopharyngeal carcinoma
  publication-title: Head Neck
– volume: 25
  start-page: 1495
  year: 2004
  end-page: 1500
  ident: CR24
  article-title: Human FOX gene family (review)
  publication-title: Int J Oncol
– volume: 191
  start-page: 649
  year: 2015
  end-page: 655
  ident: CR21
  article-title: Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma
  publication-title: Strahlenther Onkol
  doi: 10.1007/s00066-015-0840-4
– volume: 11
  start-page: 43
  year: 2011
  end-page: 47
  ident: CR12
  article-title: Proteasome inhibitory activity of thiazole antibiotics
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.11.1.13854
– volume: 66
  start-page: 1712
  year: 2006
  end-page: 1720
  ident: CR31
  article-title: Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3138
– volume: 17
  start-page: 62
  year: 2018
  ident: CR42
  article-title: Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs
  publication-title: Lipids Health Dis
  doi: 10.1186/s12944-018-0697-5
– volume: 33
  start-page: 2402
  year: 2015
  end-page: 2410
  ident: CR19
  article-title: Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial-to-mesenchymal transition pathway
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.3834
– volume: 7
  start-page: 46219
  year: 2016
  end-page: 46229
  ident: CR47
  article-title: Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer
  publication-title: Oncotarget
– volume: 374
  start-page: 22
  year: 2016
  end-page: 30
  ident: CR1
  article-title: Global trends in incidence and mortality of nasopharyngeal carcinoma
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.01.040
– volume: 14
  start-page: 231
  year: 2012
  end-page: 240
  ident: CR20
  article-title: Adenovirus-mediated RNA interference targeting FOXM1 transcription factor suppresses cell proliferation and tumor growth of nasopharyngeal carcinoma
  publication-title: J Gene Med
  doi: 10.1002/jgm.2614
– volume: 139
  start-page: 665
  year: 2006
  end-page: 670
  ident: CR34
  article-title: Sonic hedgehog-dependent proliferation in a series of patients with colorectal cancer
  publication-title: Surgery
  doi: 10.1016/j.surg.2005.10.012
– volume: 10
  start-page: 2287
  year: 2011
  end-page: 2297
  ident: CR55
  article-title: Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-11-0536
– volume: 9
  start-page: 1214
  year: 2010
  end-page: 1217
  ident: CR58
  article-title: Thiazole antibiotics against breast cancer
  publication-title: Cell Cycle
  doi: 10.4161/cc.9.6.10955
– volume: 7
  start-page: 5450
  year: 2014
  end-page: 5460
  ident: CR17
  article-title: Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells
  publication-title: Int J Clin Exp Pathol
– volume: 19
  start-page: 2181
  year: 2015
  end-page: 2192
  ident: CR41
  article-title: Thiostrepton interacts covalently with Rpt subunits of the 19S proteasome and proteasome substrates
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.12602
– volume: 28
  start-page: 2908
  year: 2009
  end-page: 2918
  ident: CR25
  article-title: FoxM1, a critical regulator of oxidative stress during oncogenesis
  publication-title: EMBO J
  doi: 10.1038/emboj.2009.239
– volume: 18
  start-page: 830
  year: 2004
  end-page: 850
  ident: CR28
  article-title: Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor
  publication-title: Genes Dev
  doi: 10.1101/gad.1200704
– volume: 788
  start-page: 321
  year: 2016
  end-page: 327
  ident: CR46
  article-title: Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2016.06.052
– volume: 27
  start-page: 887
  year: 2017
  end-page: 894
  ident: CR33
  article-title: Targeting Foxm1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian Cancer
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0000000000000969
– volume: 4
  year: 2009
  ident: CR11
  article-title: Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0005592
– volume: 8
  start-page: 34652
  year: 2017
  end-page: 34660
  ident: CR52
  article-title: DNA methylation of METTL7A gene body regulates its transcriptional level in thyroid cancer
  publication-title: Oncotarget
– volume: 2
  start-page: 106
  year: 2015
  end-page: 109
  ident: CR6
  article-title: Target-oriented design and biosynthesis of Thiostrepton-derived thiopeptide antibiotics with improved pharmaceutical properties
  publication-title: Org Chem Front
  doi: 10.1039/C4QO00288A
– volume: 4
  start-page: e6593
  year: 2009
  ident: CR10
  article-title: FoxM1 is a general target for proteasome inhibitors
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0006593
– volume: 13
  start-page: 184
  year: 2012
  end-page: 189
  ident: CR57
  article-title: Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.13.3.18875
– volume: 32
  start-page: 1327
  year: 2014
  end-page: 1334
  ident: CR36
  article-title: Targeting forkhead box transcription factors FOXM1 and FOXO in leukemia (review)
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3357
– volume: 83
  start-page: 1229
  year: 2012
  end-page: 1240
  ident: CR40
  article-title: Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2012.01.027
– volume: 8
  start-page: 37
  year: 2009
  ident: CR45
  article-title: Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-8-37
– volume: 8
  start-page: 2850
  year: 2009
  end-page: 2851
  ident: CR56
  article-title: Wild-type p53 protects normal cells against apoptosis induced by thiostrepton
  publication-title: Cell Cycle
  doi: 10.4161/cc.8.17.9414
– volume: 1867
  start-page: 58
  year: 2017
  end-page: 66
  ident: CR44
  article-title: Endoplasmic reticulum-mediated unfolded protein response and mitochondrial apoptosis in cancer
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2016.12.002
– year: 2010
  ident: CR2
  publication-title: Nasopharyngeal cancer: multidisciplinary management (medical radiology/radiation oncology)
  doi: 10.1007/978-3-540-92810-2
– volume: 30
  start-page: 946
  year: 2008
  end-page: 963
  ident: CR3
  article-title: Nasopharyngeal carcinoma-- review of the molecular mechanisms of tumorigenesis
  publication-title: Head Neck
  doi: 10.1002/hed.20833
– volume: 6
  start-page: e1801
  year: 2015
  ident: CR14
  article-title: Identification of thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2015.155
– volume: 6
  start-page: 2349
  year: 2015
  end-page: 2365
  ident: CR16
  article-title: FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells
  publication-title: Oncotarget
– volume: 36
  start-page: 3450
  year: 2017
  end-page: 3463
  ident: CR15
  article-title: Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL
  publication-title: Oncogene
  doi: 10.1038/onc.2016.495
– volume: 66
  start-page: 2153
  year: 2006
  end-page: 2161
  ident: CR30
  article-title: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3003
– volume: 68
  start-page: 716
  year: 1993
  end-page: 727
  ident: CR23
  article-title: Characterization of seven newly established nasopharyngeal carcinoma cell lines
  publication-title: Lab Investig
– volume: 66
  start-page: 3593
  year: 2006
  end-page: 3602
  ident: CR35
  article-title: FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2912
– volume: 22
  start-page: 357
  year: 1994
  end-page: 363
  ident: CR7
  article-title: The antibiotics micrococcin and thiostrepton interact directly with 23S rRNA nucleotides 1067A and 1095A
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/22.3.357
– volume: 7
  start-page: 847
  year: 2007
  end-page: 859
  ident: CR27
  article-title: The emerging roles of forkhead box (Fox) proteins in cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2223
– volume: 4
  start-page: e4849
  year: 2009
  ident: CR38
  article-title: FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0004849
– volume: 65
  start-page: 5181
  year: 2005
  end-page: 5189
  ident: CR29
  article-title: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-4059
– volume: 62
  start-page: 713
  year: 1990
  end-page: 724
  ident: CR22
  article-title: Establishment and characterization of two nasopharyngeal carcinoma cell lines
  publication-title: Lab Investig
– volume: 119
  start-page: 324
  year: 2014
  end-page: 332
  ident: CR18
  article-title: Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma
  publication-title: Ups J Med Sci
  doi: 10.3109/03009734.2014.960053
– volume: 11
  start-page: 865
  year: 2013
  end-page: 874
  ident: CR54
  article-title: TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-13-0008
– volume: 30
  start-page: 946
  year: 2008
  ident: 779_CR3
  publication-title: Head Neck
  doi: 10.1002/hed.20833
– volume: 4
  start-page: e6593
  year: 2009
  ident: 779_CR10
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0006593
– volume: 788
  start-page: 321
  year: 2016
  ident: 779_CR46
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2016.06.052
– volume: 33
  start-page: 2402
  year: 2015
  ident: 779_CR19
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.3834
– volume: 13
  start-page: 184
  year: 2012
  ident: 779_CR57
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.13.3.18875
– volume: 178
  start-page: 355
  year: 2011
  ident: 779_CR13
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2010.11.010
– volume: 2010
  start-page: 930509
  year: 2010
  ident: 779_CR43
  publication-title: Int J Cell Biol
  doi: 10.1155/2010/930509
– volume: 2
  start-page: 106
  year: 2015
  ident: 779_CR6
  publication-title: Org Chem Front
  doi: 10.1039/C4QO00288A
– volume: 119
  start-page: 324
  year: 2014
  ident: 779_CR18
  publication-title: Ups J Med Sci
  doi: 10.3109/03009734.2014.960053
– volume: 141
  start-page: 971
  year: 2015
  ident: 779_CR39
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-014-1872-3
– volume: 66
  start-page: 3593
  year: 2006
  ident: 779_CR35
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2912
– volume: 374
  start-page: 22
  year: 2016
  ident: 779_CR1
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2016.01.040
– volume: 9
  start-page: 2511
  year: 2010
  ident: 779_CR4
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0966
– volume: 12
  start-page: 1457
  year: 2015
  ident: 779_CR37
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2015.3469
– volume: 9
  start-page: 1214
  year: 2010
  ident: 779_CR58
  publication-title: Cell Cycle
  doi: 10.4161/cc.9.6.10955
– volume: 8
  start-page: 34652
  year: 2017
  ident: 779_CR52
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16147
– volume: 215
  start-page: 245
  year: 2008
  ident: 779_CR32
  publication-title: J Pathol
  doi: 10.1002/path.2355
– volume: 7
  start-page: 46219
  year: 2016
  ident: 779_CR47
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10078
– volume: 7
  start-page: 5450
  year: 2014
  ident: 779_CR17
  publication-title: Int J Clin Exp Pathol
– volume: 4
  start-page: e4849
  year: 2009
  ident: 779_CR38
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0004849
– volume: 135
  start-page: 1800
  year: 2014
  ident: 779_CR53
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28839
– volume: 10
  start-page: 2287
  year: 2011
  ident: 779_CR55
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-11-0536
– volume: 6
  start-page: e1801
  year: 2015
  ident: 779_CR14
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2015.155
– volume: 19
  start-page: 2181
  year: 2015
  ident: 779_CR41
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.12602
– volume: 37
  start-page: 2025
  year: 2017
  ident: 779_CR49
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5480
– ident: 779_CR8
– volume: 25
  start-page: 1495
  year: 2004
  ident: 779_CR24
  publication-title: Int J Oncol
– volume: 52
  start-page: 2101
  year: 2018
  ident: 779_CR48
  publication-title: Int J Oncol
– volume: 191
  start-page: 649
  year: 2015
  ident: 779_CR21
  publication-title: Strahlenther Onkol
  doi: 10.1007/s00066-015-0840-4
– volume: 17
  start-page: 62
  year: 2018
  ident: 779_CR42
  publication-title: Lipids Health Dis
  doi: 10.1186/s12944-018-0697-5
– volume: 66
  start-page: 2153
  year: 2006
  ident: 779_CR30
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3003
– volume: 11
  start-page: 43
  year: 2011
  ident: 779_CR12
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.11.1.13854
– volume: 56
  start-page: 1663
  year: 2017
  ident: 779_CR50
  publication-title: Mol Carcinog
  doi: 10.1002/mc.22622
– volume: 68
  start-page: 716
  year: 1993
  ident: 779_CR23
  publication-title: Lab Investig
– volume: 27
  start-page: 887
  year: 2017
  ident: 779_CR33
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0000000000000969
– volume: 1867
  start-page: 58
  year: 2017
  ident: 779_CR44
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2016.12.002
– volume: 6
  start-page: 2349
  year: 2015
  ident: 779_CR16
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2957
– volume: 32
  start-page: 1327
  year: 2014
  ident: 779_CR36
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3357
– volume: 7
  start-page: 847
  year: 2007
  ident: 779_CR27
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2223
– volume: 11
  start-page: 865
  year: 2013
  ident: 779_CR54
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-13-0008
– volume: 36
  start-page: 3450
  year: 2017
  ident: 779_CR15
  publication-title: Oncogene
  doi: 10.1038/onc.2016.495
– volume: 10
  start-page: e0132839
  year: 2015
  ident: 779_CR51
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0132839
– volume: 65
  start-page: 5181
  year: 2005
  ident: 779_CR29
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-4059
– volume: 36
  start-page: 1398
  year: 2014
  ident: 779_CR5
  publication-title: Head Neck
  doi: 10.1002/hed.23464
– volume: 83
  start-page: 1229
  year: 2012
  ident: 779_CR40
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2012.01.027
– volume-title: Nasopharyngeal cancer: multidisciplinary management (medical radiology/radiation oncology)
  year: 2010
  ident: 779_CR2
  doi: 10.1007/978-3-540-92810-2
– volume: 66
  start-page: 1712
  year: 2006
  ident: 779_CR31
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3138
– volume: 8
  start-page: 37
  year: 2009
  ident: 779_CR45
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-8-37
– volume: 18
  start-page: 830
  year: 2004
  ident: 779_CR28
  publication-title: Genes Dev
  doi: 10.1101/gad.1200704
– volume: 8
  start-page: 1966
  year: 2009
  ident: 779_CR26
  publication-title: Cell Cycle
  doi: 10.4161/cc.8.12.8708
– volume: 139
  start-page: 665
  year: 2006
  ident: 779_CR34
  publication-title: Surgery
  doi: 10.1016/j.surg.2005.10.012
– volume: 28
  start-page: 2908
  year: 2009
  ident: 779_CR25
  publication-title: EMBO J
  doi: 10.1038/emboj.2009.239
– volume: 62
  start-page: 713
  year: 1990
  ident: 779_CR22
  publication-title: Lab Investig
– volume: 22
  start-page: 357
  year: 1994
  ident: 779_CR7
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/22.3.357
– volume: 14
  start-page: 231
  year: 2012
  ident: 779_CR20
  publication-title: J Gene Med
  doi: 10.1002/jgm.2614
– volume: 4
  year: 2009
  ident: 779_CR11
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0005592
– volume: 8
  start-page: 2850
  year: 2009
  ident: 779_CR56
  publication-title: Cell Cycle
  doi: 10.4161/cc.8.17.9414
– volume: 7
  start-page: 2022
  year: 2008
  ident: 779_CR9
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0188
SSID ssj0003974
Score 2.2980645
Snippet Summary Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in...
Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal...
SummaryBackground Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 264
SubjectTerms Adenocarcinoma
Anti-Bacterial Agents - pharmacology
Antibiotics
Anticancer properties
Antineoplastic Agents - pharmacology
Assaying
Biosynthesis
Cancer
Cell Line, Tumor
Cell migration
Cell Movement - drug effects
Cell proliferation
Cell Proliferation - drug effects
Cell Survival - drug effects
Cell viability
Cellular stress response
Chemical compounds
Choline
Data processing
Gene Expression Regulation, Neoplastic - drug effects
Humans
Medicine
Medicine & Public Health
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Carcinoma - genetics
Nasopharyngeal Neoplasms - drug therapy
Nasopharyngeal Neoplasms - genetics
Oncology
Oxidative stress
Pancreas
Pancreatic cancer
Pharmacology
Pharmacology/Toxicology
Preclinical Studies
Protein folding
Proteins
Studies
Thiostrepton
Thiostrepton - pharmacology
Throat cancer
Wound healing
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB58gHgRXV_riwjixQbaJM2mx0UUEVY8uCB4KEk2iwvaLu562H_vpE_FB3htpmnIZJJvOplvAM5CwV3Sc4w6YwQViZU0UUJTg96Eiq3lriDSHtzJm6G4fYwfq6SwWX3bvQ5JFjv1p2Q3yf01yYR6DpqE8mVYjdF39-t6yPrN_osnbMPoLZOkV6XK_NzH1-PoG8b8Fh8tjp3rTdio8CLplwregiWXdWBtUEXEO3B-X3JPLwLy0KZSzQJyTu5bVurFNjz1yRR3tyoRkrQs3yQfk_nzJPdZI1NEggHRpKD7RCmc9omZ5NhjQCYZPvZFD_TbAkeKrdbXIcryV70Dw-urh8sbWlVWoBbhz5yqsQqFdaHTxo6kx1gaTdcwjSbNlP_lzyN0uUfOP2dKWisMHmIucZqFDv3aXVjJ8sztAzFcSBOJSJuRFYhNTA_9Ujv2tDXSKS26ENUTnNqKdtxXv3hJW8Jkr5QUlZIWSkl5Fy6ad6Yl6caf0ke13tLKAGcp865sFMmQdeG0aUbT8fEQnbn8vZRBgCliHOReqe_mcxyRM4-V6kJQL4C289_HcvA_8UNYZ95_L24CHcHK_O3dHSPImZuTYk1_AJ6t8I8
  priority: 102
  providerName: Springer Nature
Title A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma
URI https://link.springer.com/article/10.1007/s10637-019-00779-3
https://www.ncbi.nlm.nih.gov/pubmed/30993588
https://www.proquest.com/docview/2210211602
https://www.proquest.com/docview/2210951454
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED62FsZextr9StcVDUZfZjFbUhT5qWQjXdloCaOBjD0YSVFoYLPTJn3If987W7EpZX0ySLIsfDrdd5LuO4BPqZIhHwTBg3OKq9xrnhtluUNvwvS9l6Em0j6_0GcT9WPan8YNt1W8VrldE-uFelZ52iP_Isg3yTKdipPlNaesUXS6GlNoPIVdoi4j52swbR2uFG1ty-2t83wQg2Zi6JyWdOky58Rok3N53zA9QJsPTkprA3T6El5E5MiGjaj34Eko9-HZeTwb34fjccNCvUnYZRdUtUrYMRt3_NSbV_BnyJa4zsWQSNbxfbNqztZXi4riR5aICRNmWU38ia1QAAu3qLDHhC1KLKb0B_ZmgyPFWk8Zicrqn30Nk9PR5bczHnMscI9AaM3N3KTKhzRY52ea0JZFJXbConILQ5v_MkPnexaoXBjtvXJozkIerEgDerhvYKesyvAOmJNKu0xl1s28QpTiBuih-jkR2OhgrOpBtv3BhY8E5JQH42_RUSeTUAoUSlELpZA9-Ny-s2zoNx5tfbiVWxFVcVV0E6cHH9tqVCI6GbFlqG6bNgg1VR8H-baRd_s5iRha9o3pQbKdAF3n_x_LweNjeQ_PBXnu9R2gQ9hZ39yGDwhv1u6onsNHsDv8_vvnCJ9fRxfjX1g6EcM7T7_3fQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Rb9MwED6NTgJeEAwYhQFGgr0Qa4ntus7DhAZs6thaVaiTJvEQbNcVlSApayfUP8Vv3DlxEqGJve3VdhzLdz5_Z_u-A3gbC-7SvmPUGSOoSK2kqRKaGvQmVM9a7koi7eFIDs7El_Pe-Qb8rWNh_LPK2iaWhnpaWH9Gvse8b5IkMmYfFr-pzxrlb1frFBqVWpy49R902Zb7x59Rvu8YOzqcfBrQkFWAWtz6V1TNVCysi502dio9vtCotoZpVGem_HE3T9DdnDpfzpS0Vhg04C51msUOfTrs9w5sCo5QoQObHw9H46-N7cfdvWETl2naD2E6IVhPcv_MM6WeQyel_N-t8Bq-vXY3W255Rw_hQcCq5KBSrkew4fItuDsMt_FbsDuueK_XEZm0YVzLiOySccuIvX4M3w7IAi1rCMIkLcM4KWZk9WNe-IiVBaLQiGhSUo1iKxT53MwL7DEi8xyLfcIFfbHGkWKt9TmQ8uKXfgJntzL_T6GTF7l7BsRwIU0iEm2mViAuMn30ie3MU-ZIp7ToQlJPcGYD5bnPvPEza8mavVAyFEpWCiXjXXjffLOoCD9ubL1Tyy0Li3-ZtarahTdNNS5bfxejc1dcVm0Q3IoeDnK7knfzO46onfeU6kJUK0Db-f_H8vzmsbyGe4PJ8DQ7PR6dvID7zJ8blC-QdqCzurh0LxFcrcyroNEEvt_2IroCf_QwuA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB2VIlVcEJSPLhQwEvRCrCa2N3EOCFWUVUtptYdWWolDsL1esRIkS3crtH-NX8dM4iRCFb31ajuO5RmP39ieNwBvYiV9nnnBvbWKq9ylPNfKcIvehB46J31NpH16lh5dqM-T4WQD_rSxMPSssrWJtaGeVo7OyPcF-SZJksZifxaeRYwPRx8WvzhlkKKb1jadRqMiJ379G9235fvjQ5T1WyFGn84_HvGQYYA7hAErrmc6Vs7H3lg3TQlrGFRhKwyqttB09C0TdD2nnsqFTp1TFo25z70RsUf_Dvu9A3czidsmrqVs0jl7Me7zHa94mudZCNgJYXuppAefOSc2nZzLfzfFa0j32i1tvfmNHsD9gFrZQaNmD2HDl9uwdRru5bdhb9wwYK8jdt4HdC0jtsfGPTf2-hF8PWALtLEhHJP1XOOsmrHV93lFsSsLxKMRM6wmHcVWKPy5nVfYY8TmJRZT6gVzucaRYq2jbEhl9dM8hotbmf0nsFlWpd8BZqVKbaISY6dOIUKyGXrHbkbkOanXRg0gaSe4cIH8nHJw_Ch62mYSSoFCKWqhFHIA77pvFg31x42td1u5FcEMLIteaQfwuqvGBUy3Mqb01VXTBmGuGuIgnzby7n4nEb_LodYDiFoF6Dv__1ie3TyWV7CFS6f4cnx28hzuCTpAqJ8i7cLm6vLKv0CUtbIva3Vm8O22189foh4ziA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+preclinical+evaluation+of+thiostrepton%2C+a+natural+antibiotic%2C+in+nasopharyngeal+carcinoma&rft.jtitle=Investigational+new+drugs&rft.au=Hsu%2C+Yen-Bin&rft.au=Lan%2C+Ming-Chin&rft.au=Kuo%2C+Yu-Lun&rft.au=Huang%2C+Chi-Ying+F&rft.date=2020-04-01&rft.eissn=1573-0646&rft.volume=38&rft.issue=2&rft.spage=264&rft_id=info:doi/10.1007%2Fs10637-019-00779-3&rft_id=info%3Apmid%2F30993588&rft.externalDocID=30993588
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6997&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6997&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6997&client=summon